NYU Langone’s Laura and Isaac Perlmutter Cancer Center

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

• Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

  New York, New York 10016

  30 vizsgálat

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

  New York, New York 10016

  10 vizsgálat

• Laura and Isaac Perlmutter Cancer Center

  New York, New York 10016

  9 vizsgálat

• NYU Langone Health Perlmutter Cancer Center

  New York, New York 10016

  7 vizsgálat

• NYU Langone Health Laura and Isaac Perlmutter Cancer Center

  New York, New York 10016

  5 vizsgálat

• Perlmutter Cancer Center at NYU Langone Health

  New York, New York 10016

  5 vizsgálat

• Perlmutter Cancer Center, NYU Langone Health

  New York, New York 10016

  5 vizsgálat

• Laura and Isaac Perlmutter Cancer Center/ NYU Langone Health

  New York, New York 10016

  3 vizsgálat

  • NCT05783622Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

  • NCT05538572A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

  • NCT01042379I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    Contact: Yannis Karamitas

• Laura & Isaac Perlmutter Cancer Center - NYU ACC

  New York, New York 10016

  3 vizsgálat

  • NCT06012435A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  • NCT05580562ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

    Contact: Clinical Trial Disclosure & Transparency

  • NCT04553133PF-07104091 as a Single Agent and in Combination Therapy

• NYU Perlmutter Cancer Center

  New York, New York 10016

  3 vizsgálat

  • NCT02975934A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  • NCT02621151Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

  • NCT02752685Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

• Perlmutter Cancer Center

  New York, New York 10016

  3 vizsgálat

  • NCT02546102Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

  • NCT05828511A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  • NCT01844986Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

• Perlmutter Cancer Center - 34th Street

  New York, New York 10016

  3 vizsgálat

  • NCT07128199A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

    Contact: Taiho Oncology, Inc.

  • NCT06010329A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

    Contact: Xiaoyang Xia

  • NCT04256317A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Contact: Taiho Oncology, Inc.

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0034)

  New York, New York 10016

  2 vizsgálat

  • NCT04165083KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

  • NCT04165798KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

    Contact: Toll Free Number

• Laura and Isaac Perlmutter Cancer Center (Site 0034)

  New York, New York 10016

  2 vizsgálat

  • NCT04165096KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

  • NCT04165070KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

    Contact: Toll Free Number

• Laura & Isaac Perlmutter Cancer Center

  New York, New York 10016

  2 vizsgálat

  • NCT06549465Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

    Contact: David Wise, MD (principal investigator)

  • NCT05548296A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

    Contact: Karen Estok

• Laura & Isaac Perlmutter Cancer Center - NYU Langone Health

  New York, New York 10016

  2 vizsgálat

  • NCT05951179Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

    Contact: Chief Scientific Operations Officer

  • NCT05252390NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

• Perlmutter Cancer Center - Sunset Park

  Brooklyn, New York 11220

  2 vizsgálat

  • NCT06760637Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  • NCT06638307A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    Contact: Nancy Chan (principal investigator)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0002)

  New York, New York 10016

  1 vizsgálat

  • NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0006)

  New York, New York 10016

  1 vizsgálat

  • NCT03783078Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0019)

  New York, New York 10016

  1 vizsgálat

  • NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0023)

  New York, New York 10016

  1 vizsgálat

  • NCT03797326Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0038)

  New York, New York 10016

  1 vizsgálat

  • NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0111)

  New York, New York 10016

  1 vizsgálat

  • NCT06833073A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

    Contact: Study Coordinator

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 1074)

  New York, New York 10016

  1 vizsgálat

  • NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 2014)

  New York, New York 10016

  1 vizsgálat

  • NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 3042)

  New York, New York 10016

  1 vizsgálat

  • NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

• Laura and Isaac Perlmutter Cancer Center (Site 0003)

  New York, New York 10016

  1 vizsgálat

  • NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    Contact: Study Coordinator

• Laura and Isaac Perlmutter Cancer Center (Site 0010)

  New York, New York 10016

  1 vizsgálat

  • NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

• Laura and Isaac Perlmutter Cancer Center (Site 0076)

  New York, New York 10016

  1 vizsgálat

  • NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    Contact: Study Coordinator

• Laura and Isaac Perlmutter Cancer Center (Site 0137)

  New York, New York 10016

  1 vizsgálat

  • NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

• Laura and Isaac Perlmutter Cancer Center (Site 1016)

  New York, New York 10016

  1 vizsgálat

  • NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

• Laura and Isaac Perlmutter Cancer Center (Site 1582)

  New York, New York 10016

  1 vizsgálat

  • NCT04428151Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

• Laura and Isaac Perlmutter Cancer Center (Site 3016)

  New York, New York 10016

  1 vizsgálat

  • NCT04626518Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

• Laura and Isaac Perlmutter Cancer Center (Site 4106)

  New York, New York 10016

  1 vizsgálat

  • NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

• Laura and Isaac Perlmutter Cancer Center (Site 5016)

  New York, New York 10016

  1 vizsgálat

  • NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

    Contact: Study Coordinator

• Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC

  New York, New York 10016

  1 vizsgálat

  • NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    Contact: Revolution Medicines Study Director

• Laura & Isaac Perlmutter Cancer Ctr

  New York, New York 10016

  1 vizsgálat

  • NCT04463771Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

• NYU Investigational Pharmacy, Laura & Isaac Perlmutter Cancer Center

  New York, New York 10016

  1 vizsgálat

  • NCT04958785Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

• NYU Langone Cancer Center

  New York, New York 10016

  1 vizsgálat

  • NCT05242822A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

• NYU Langone Health, Laura & Isaac Perlmutter Cancer Center

  New York, New York 10016

  1 vizsgálat

  • NCT05682443ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

• NYU Langone Health Perlmutter Cancer Center - Manhattan

  Manhattan, New York 10016

  1 vizsgálat

  • NCT07567014Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

    Contact: Oscar B. Lahoud, MD

• NYU Langone Health-Perlmutter Cancer Center (Site 1917)

  New York, New York 10016

  1 vizsgálat

  • NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

• NYU Langone Health Perlmutter Cancer Center - Sunset Park

  Brooklyn, New York 11220

  1 vizsgálat

  • NCT07567014Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

    Contact: Oscar B. Lahoud, MD

• NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 226141

  New York, New York 10016-4744

  1 vizsgálat

  • NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

• NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 252708

  New York, New York 10016-4744

  1 vizsgálat

  • NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

• NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943

  New York, New York 10016

  1 vizsgálat

  • NCT06158958A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

• Perlmutter Cancer Center - 38th Street

  New York, New York 10016

  1 vizsgálat

  • NCT06619236Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

• Perlmutter Cancer Center at NYU Langone Health

  Mineola, New York 11501

  1 vizsgálat

  • NCT05952934Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

    Contact: Zujun Li, MD

• Perlmutter Cancer Center at NYU Langone Health (contact for more locations)

  New York, New York 10016

  1 vizsgálat

  • NCT07659795A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    Contact: Rafael Winograd, MD, PhD

• Perlmutter Cancer Center - Manhattan - 34th Street

  New York, New York 10016

  1 vizsgálat

  • NCT05382286Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

• Perlmutter Cancer Centre

  New York, New York 10016

  1 vizsgálat

  • NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)